Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022117798 - IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV

Publication Number WO/2022/117798
Publication Date 09.06.2022
International Application No. PCT/EP2021/084132
International Filing Date 03.12.2021
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 39/09 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
09Streptococcus
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/39 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
CPC
A61K 2039/521
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
52Bacterial cells; Fungal cells; Protozoal cells
521inactivated (killed)
A61K 2039/542
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
541Mucosal route
542oral/gastrointestinal
A61K 2039/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
58raising an immune response against a target which is not the antigen used for immunisation
A61K 39/09
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus; , streptococcus
A61K 39/092
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus; , streptococcus
092Streptococcus
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Applicants
  • DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN [DE]/[DE]
Inventors
  • KRUGLOV, Andrey
Agents
  • HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE
Priority Data
20211707.303.12.2020EP
21164128.723.03.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV
(FR) COMPOSITIONS IMMUNOGÈNES POUR LA PRODUCTION D'ANTICORPS NEUTRALISANTS CONTRE LE SRAS-COV
Abstract
(EN) The invention relates to an immunogenic composition for use as a medicament to prevent and/or treat a medical condition associated with a SARS-CoV infection, said composition comprising one or more bacteria of the human microbiota and/or immunogenic parts thereof, wherein said composition is capable of inducing acquired immunity to said infection. The invention further relates to isolated bacteria of the human microbiota that bind to a neutralising antibody that recognises the spike protein of SARS-CoV, preferably the spike protein of SARS-CoV2. In another aspect, the invention relates to an in vitro method for the diagnosis, prognosis, risk stratification and/or therapy management of a human subject with an increased risk of an adverse event associated with a medical condition associated with a SARS-CoV infection (preferably with SARS-CoV-2).
(FR) L'invention concerne une composition immunogène destinée à être utilisée en tant que médicament pour prévenir et/ou traiter un état médical associé à une infection par le SRAS-CoV, ladite composition comprenant une ou plusieurs bactéries du microbiote humain et/ou des parties immunogènes de celui-ci, ladite composition étant capable d'induire une immunité acquise à ladite infection. L'invention concerne en outre des bactéries isolées du microbiote humain qui se lient à un anticorps neutralisant qui reconnaît la protéine de spicule du SRAS-CoV, de préférence la protéine de spicule du SRAS-CoV2. Dans un autre aspect, l'invention concerne un procédé in vitro pour le diagnostic, le pronostic, la stratification des risques et/ou la gestion de la thérapie d'un sujet humain présentant un risque accru d'un événement indésirable associé à un état médical associé à une infection par le SRAS-CoV (de préférence par le SRAS-CoV-2).
Related patent documents
Latest bibliographic data on file with the International Bureau